

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
15 September 2022 (15.09.2022)



(10) International Publication Number  
**WO 2022/189620 A1**

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 1/00 (2006.01)  
C07K 14/12 (2006.01)

(21) International Application Number:

PCT/EP2022/056318

(22) International Filing Date:

11 March 2022 (11.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21305296.2 11 March 2021 (11.03.2021) EP  
22305236.6 02 March 2022 (02.03.2022) EP

(71) Applicants: INSTITUT CURIE [FR/FR]; 26 rue d'Ulm, 75005 PARIS (FR). MNEMO THERAPEUTICS [FR/FR]; 101 boulevard Murat, 75016 PARIS (FR). INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR).

(72) Inventors: AMIGORENA, Sebastian; 32 rue des cordeliers, 75013 PARIS (FR). BURBAGE, Marianne; 46 rue Myrha, 75018 PARIS (FR). HOUY, Alexandre; 17 rue Rosa Parks, 94400 VITRY SUR SEINE (FR). WALTERFALL, Joshua; 4 rue d'Alleray, 75015 PARIS (FR). STERN, Marc-Henri; 41 rue Boulard, 75014 PARIS (FR). SADACCA, Benjamin; 271 rue de Belleville, 75019 PARIS (FR). MERLOTTI IPPOLITO, Antonela; 144 avenue Parmentier, 75011 PARIS (FR). GOUDOT, Christel; 18 avenue Yves Cariou, 93150 LE BLANC MESNIL (FR). LOPEZ LASTRA, Silvia; c/o INSTITUT CURIE, 26 rue Ulm, 75005 PARIS (FR). ARRIBAS DE SANDOVAL, Yagos; 11D rue Marguerite de Rochechouart, 75009 Paris (FR).

(74) Agent: PLASSERAUD IP; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TRANSMEMBRANE NEOANTIGENIC PEPTIDES

(57) Abstract: The present disclosure provides transmembrane chimeric proteins derived from transposable element (TE)-exon fusion transcripts, as well as nucleic acids, antibodies, CARs, non-HLA restricted TCR and immune cells targeting such chimeric proteins that can be used in cancer therapy.

WO 2022/189620 A1